Blog
59 Articles
RASolute 302 Trial for KRAS and Other RAS Mutations Recruiting at Multiple Sites
Dr. Hani Babiker is optimistic about the new drug to treat patients with KRAS mutations, now in a phase III trial.
Highlights from the 2025 AACR Annual Meeting
Drugs to target KRAS, better imaging for earlier detection, and cachexia prediction are among the research highlights from AACR 2025.
New Phase III Clinical Trial Actively Recruiting
Dr. Zev Wainberg is enthusiastic about the phase III clinical trial combining a new drug and standard chemo to make immunotherapy more effective.
Determined to Win
After a metastatic pancreatic cancer diagnosis, Linda Chambless sought a second opinion, which led her to a clinical trial.
Pancreatic Cancer Research Highlights from ASCO GI 2025
Read about the pancreatic cancer research highlights from the ASCO GI 2025 conference, where treatments and quality-of-life were discussed.
A Look Back at Research in 2024
Research in 2024 focused on personally tailored treatments, countering the most difficult effects of pancreatic cancer, and clinical trials.
Research: The Next Generation
AACR young researchers come from all over the world, and add their perspectives to pancreatic cancer studies.
A New Approach to Overcome Drug Resistance
Dr. Despina Siolas is leading one of the sites where a new drug combination to combat the effects of KRAS mutations is under trial.
Genetic Testing Guided My Treatment Plan
Ryan Dwars already knew there was pancreatic cancer in his family so when he was diagnosed he asked for genetic testing right away.
Targeting a KRAS Variant in Advanced Pancreatic Cancer
Researchers are testing a new drug that targets KRAS variant G12D in conjunction with different chemotherapies.
AACR Special Conference Highlights Advances in Pancreatic Cancer Research
Here are some of the most interesting highlights from the 2024 AACR Special Conference on Pancreatic Cancer Research.
No Time for Self-Pity
When David Smith started losing weight after a diabetes diagnosis, his daughter-in-law was concerned because she had seen this before.
A New Combination Targeting the RAS Pathway
Researchers are testing two new drugs that target the RAS pathway, to make standard chemotherapy more effective.
Don’t Let Doctors Tell You Nothing’s Wrong
After a long road to diagnosis Brandon Stone learned he has a BRCA2 genetic mutation that impacts his treatment.
Pancreatic Cancer Research Updates from ASCO 2024
Learn about the latest developments in pancreatic cancer research into immunotherapy and chemotherapy from the ASCO 2024 meeting.